Genentech takes the health and safety of our patients, customers, employees and local communities very seriously, and we are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page.

Neuroscience

One particularly exciting area where we are placing our Partnering efforts is in Neuroscience. Following the science is taking us into an area of enormous need and opportunity for scientific progress in diseases of the brain and nervous system.

Four efforts also built one of the strongest and most diverse pipelines in the industry with four late stage investigational medicines and 2 potential new molecular entity (NME) approvals in 2020, spanning the spectrum of nervous system disorders from the rarest to the most common.

Partnering opportunities we are looking for:

  • Neurodegeneration (e.g. Alzheimer's disease, Parkinson's disease, Huntington disease, Amyotrophic lateral sclerosis)
  • Neuroinflammation (e.g. Multiple sclerosis)
  • Neurodevelopmental (e.g. Autistic spectrum disorder)
  • Pain (non-opioid treatments for chronic pain)

Example partnerships

Convelo Therapeutics – collaboration to discover and develop novel remyelinating medicines for patients with neurological disorders

Kineta Inc. – collaboration to explore novel non-opioid treatments for chronic pain

Your dedicated partnering leads in Neuroscience


Tom Zioncheck, Head of Neuroscience, Ophthalmology and Rare Diseases, Pharma Partnering


J.C. Lopez, Search & Evaluation Lead Neuroscience, Ophthalmology & Rare Diseases, Pharma Partnering